Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Legend Signs $1.2 Billion Agreement Selling Global Rights for DLL3 CAR-T to Novartis

publication date: Nov 13, 2023

Legend Biotech (NASDAQ: LEGN), a New Jersey-Nanjing CAR-T biotech, partnered its DLL3 (delta-like ligand 3) CAR-T candidates to Novartis in a $1.2 billion agreement ($100 million upfront). Legend will start a US trial of LB2102 in patients with extensive stage small cell lung cancer and large cell neuroendocrine carcinoma. Novartis will own worldwide rights to develop, manufacture and commercialize the DLL3 group of cell therapies, and it may use its T-Charge™ platform to manufacture the candidates. In 2017, Legend, then a Genscript subsidiary headquartered in Nanjing, stunned the world when its BCMA CAR-T produced a better than 90% response in pretreated multiple myeloma patients. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here